← Back to Home

Mouse tau still reduced by 84% six months after a single dose: AviadoBio announces new Alzheimer’s gene therapy data

AVB-406 aims to enable brain cells to keep reducing tau production, and the latest animal results offer clues about the durability of its effects. The company plans to begin a first-in-human trial in 2027, but there is no human evidence yet that lowering the protein can improve memory and daily functioning.

By SURL BioNews

To tackle Alzheimer’s disease by lowering tau protein, researchers must answer not only “how much can it be reduced?” but also “how long can the reduction last?” Preclinical data announced by AviadoBio on October 29 offer new clues to the latter question: six months after mice received a single dose of the experimental gene therapy AVB-406, endogenous tau protein was still reduced by 84%. This is animal evidence of a durable effect, but key steps remain before it can be shown to slow disease progression in patients.

These studies were presented at the 2026 European Society of Gene and Cell Therapy (ESGCT) annual meeting. AVB-406 uses the company’s vMiX RNA interference platform, with an adeno-associated virus (AAV) vector delivering gene-silencing instructions to reduce expression of MAPT, the gene encoding tau protein. Its design combines a viral capsid capable of crossing the blood–brain barrier with a neuron-selective promoter, aiming to concentrate its effects in brain neurons and sustain them after a single intravenous dose.

The company’s announcement, and the same announcement published by BioSpace and SV Health Investors, state that a single intravenous dose reduced MAPT messenger RNA (mRNA) in mouse brains by up to 79%, while microRNA (miRNA) expression was confined to the central nervous system. At the six-month follow-up, MAPT mRNA remained suppressed, accompanied by the 84% reduction in tau protein noted above. These measures reflect changes in genetic messages and protein levels, respectively; they cannot be interpreted directly as improved memory or halted neurodegeneration.

Parkinson’s disease research announced at the same meeting directed the platform toward SNCA, the gene encoding α-synuclein. In tests that included human induced pluripotent stem cell-derived neurons, two candidate miRNA sequences reduced SNCA mRNA by approximately 80%; in pilot animal studies, the best-performing candidate sequence achieved up to 78% silencing. This provides a basis for further development of AVB-SNCA, but experiments in human cells are not equivalent to treatment outcomes in humans.

These data currently come primarily from a company announcement about its conference presentations; the two external publications also reproduce the announcement and do not constitute independent validation. The publicly available material does not fully describe sample sizes, statistical uncertainty, or the conditions of each experiment, making it difficult to assess the robustness of the results or compare the strengths and weaknesses of different models and candidate therapies. Delivery efficiency and durability in mice also cannot be directly extrapolated to the human brain.

Background context

Research into lowering tau has explored different delivery routes, including nonviral RNA interference therapies that have produced early human biomarker evidence. AVB-406, meanwhile, seeks to use a viral vector to enable cells to continuously produce silencing signals. The species, tissues, and administration routes involved in these approaches differ, so their percentage reductions should not be ranked directly against one another; the central question is whether lowering tau can translate into functional improvements that patients can perceive, with acceptable safety.

AviadoBio says no adverse clinical signs have been observed in animal studies to date, toxicology studies compliant with Good Laboratory Practice (GLP) are ongoing, and it plans to advance AVB-406 into a first-in-human trial in early Alzheimer’s disease in 2027. The absence of obvious abnormalities in animals is not sufficient to establish safety in humans; for a therapy intended to have lasting effects, the appropriate degree of sustained suppression and its long-term consequences will also be questions that subsequent research must answer.

References

  1. AviadoBio
  2. BioSpace (Business Wire press release)
  3. SV Health Investors (portfolio-company announcement)